Compare Stocks: SLNO, AXSM, RDY, and CRNX

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$206.68	$223.12	$112.90 ▼ $260.19	$10.83B	0.71	639,899 shs	438,239 shs
CRNX Crinetics Pharmaceuticals	$84.95	$79.85	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
RDY Dr. Reddy's Laboratories	$11.97	$12.54	$11.36 ▼ $15.67	$9.99B	0.28	2.46 million shs	2.34 million shs
SLNO Soleno Therapeutics	$53.01	$47.81	$29.43 ▼ $90.32	$2.76B	-2.22	1.75 million shs	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	0.00%	+4.11%	-2.85%	-15.86%	+65.12%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	+1.03%	+142.92%	+138.56%
RDY Dr. Reddy's Laboratories	0.00%	-1.48%	-2.01%	-10.38%	-16.50%
SLNO Soleno Therapeutics	0.00%	0.00%	0.00%	0.00%	-24.02%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
AXSM Axsome Therapeutics	$206.68	$223.12	$112.90 ▼ $260.19	$10.83B	0.71	639,899 shs	438,239 shs
CRNX Crinetics Pharmaceuticals	$84.95	$79.85	$30.25 ▼ $85.01	$9.01B	0.08	2.43 million shs	N/A
RDY Dr. Reddy's Laboratories	$11.97	$12.54	$11.36 ▼ $15.67	$9.99B	0.28	2.46 million shs	2.34 million shs
SLNO Soleno Therapeutics	$53.01	$47.81	$29.43 ▼ $90.32	$2.76B	-2.22	1.75 million shs	N/A

(Almost) Everything You Need To Know About The EV Market

Looking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
AXSM Axsome Therapeutics	0.00%	+4.11%	-2.85%	-15.86%	+65.12%
CRNX Crinetics Pharmaceuticals	0.00%	0.00%	+1.03%	+142.92%	+138.56%
RDY Dr. Reddy's Laboratories	0.00%	-1.48%	-2.01%	-10.38%	-16.50%
SLNO Soleno Therapeutics	0.00%	0.00%	0.00%	0.00%	-24.02%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
AXSM Axsome Therapeutics	2.91	Moderate Buy	$267.60	29.48% Upside
CRNX Crinetics Pharmaceuticals	2.24	Hold	$81.00	-4.65% Downside
RDY Dr. Reddy's Laboratories	1.50	Reduce	N/A	N/A
SLNO Soleno Therapeutics	2.00	Hold	$73.00	37.71% Upside

Current Analyst Ratings Breakdown

Latest SLNO, AXSM, RDY, and CRNX Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/2/2026	CRNX Crinetics Pharmaceuticals	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Neutral
8/31/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$290.00
8/24/2026	AXSM Axsome Therapeutics	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/24/2026	AXSM Axsome Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/18/2026	AXSM Axsome Therapeutics	Zacks Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Strong Sell ➝ Hold
8/12/2026	AXSM Axsome Therapeutics	Mizuho Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Outperform	$306.00 ➝ $316.00
8/11/2026	AXSM Axsome Therapeutics	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Outperform	$304.00 ➝ $297.00
8/11/2026	AXSM Axsome Therapeutics	Morgan Stanley Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Equal Weight	$242.00 ➝ $251.00
8/11/2026	AXSM Axsome Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$260.00 ➝ $275.00
8/11/2026	AXSM Axsome Therapeutics	UBS Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy ➝ Market Perform
8/11/2026	AXSM Axsome Therapeutics	Wells Fargo & Company Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Overweight	$255.00 ➝ $256.00

(Data available from 9/8/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
AXSM Axsome Therapeutics	$638.50M	16.96	N/A	N/A	$1.75 per share	118.10
CRNX Crinetics Pharmaceuticals	$7.70M	1,170.54	N/A	N/A	$11.23 per share	7.56
RDY Dr. Reddy's Laboratories	$3.58B	2.79	$0.85 per share	14.13	$4.86 per share	2.46
SLNO Soleno Therapeutics	$285.01M	9.69	$0.43 per share	124.10	$9.51 per share	5.57

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
AXSM Axsome Therapeutics	-$183.17M	-$3.75	N/A	50.91	N/A	-24.68%	-265.55%	-28.10%	11/2/2026 (Estimated)
CRNX Crinetics Pharmaceuticals	-$465.32M	-$5.04	N/A	N/A	N/A	-1,189.88%	-44.22%	-39.77%	11/5/2026 (Estimated)
RDY Dr. Reddy's Laboratories	$456M	$0.44	27.21	21.00	2.50	10.15%	9.49%	6.32%	10/23/2026 (Estimated)
SLNO Soleno Therapeutics	$20.89M	$1.77	29.95	9.89	N/A	33.70%	22.85%	18.25%	N/A

Latest SLNO, AXSM, RDY, and CRNX Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/10/2026	Q2 2026	AXSM Axsome Therapeutics	-$0.8921	-$0.99	-$0.0980	-$0.99	$221.11 million	$218.38 million
8/3/2026	Q2 2026	CRNX Crinetics Pharmaceuticals	-$1.18	-$1.14	+$0.04	-$1.14	$14.84 million	$25.12 million
7/23/2026	Q1 26/27	RDY Dr. Reddy's Laboratories	$0.0918	$0.06	-$0.0318	$0.06	$850.56 million	$850.26 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
AXSM Axsome Therapeutics	N/A	N/A	N/A	N/A	N/A
CRNX Crinetics Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
RDY Dr. Reddy's Laboratories	$0.06	0.50%	+6.96%	13.64%	N/A
SLNO Soleno Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
AXSM Axsome Therapeutics	1.52	1.43	1.34
CRNX Crinetics Pharmaceuticals	N/A	15.57	15.53
RDY Dr. Reddy's Laboratories	0.03	1.90	1.39
SLNO Soleno Therapeutics	0.10	5.62	5.32

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
AXSM Axsome Therapeutics	81.49%
CRNX Crinetics Pharmaceuticals	98.51%
RDY Dr. Reddy's Laboratories	3.85%
SLNO Soleno Therapeutics	97.42%

Insider Ownership

Company	Insider Ownership
AXSM Axsome Therapeutics	20.60%
CRNX Crinetics Pharmaceuticals	3.80%
RDY Dr. Reddy's Laboratories	2.00%
SLNO Soleno Therapeutics	6.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
AXSM Axsome Therapeutics	380	52.38 million	41.59 million	Optionable
CRNX Crinetics Pharmaceuticals	210	106.10 million	102.06 million	Optionable
RDY Dr. Reddy's Laboratories	27,527	834.67 million	817.97 million	Optionable
SLNO Soleno Therapeutics	30	52.12 million	48.78 million	Optionable

SLNO, AXSM, RDY, and CRNX Headlines

Recent News About These Companies

Kuehn Law Encourages Investors of Soleno Therapeutics, Inc. to Contact Law Firm

September 2, 2026 | prnewswire.com

SLNO 8-DAY DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Securities Class Action Alleging Hyperphagia Drug Launch Disruptions - Hagens Berman

May 11, 2026 | prnewswire.com

Soleno Merger With Neurocrine Puts Profitability And Valuation In Focus

May 10, 2026 | finance.yahoo.com

SOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO

May 5, 2026 | newsfilecorp.comN

SOLENO DEADLINE TODAY: ROSEN, TRUSTED INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO

May 5, 2026 | newsfilecorp.comN

INVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Soleno Therapeutics, Inc. of Class Action Lawsuit and Upcoming Deadlines – SLNO

May 5, 2026 | globenewswire.com

SLNO DEADLINE ALERT: Hagens Berman Alerts Soleno Therapeutics (SLNO) Investors to Today's Lead Plaintiff Deadline in Securities Class Action

May 5, 2026 | prnewswire.com

DEADLINE ALERT for EOSE, SLNO, and NKTR: The Law Offices of Frank R. Cruz Reminds Investors of Class Actions on Behalf of Shareholders

May 5, 2026 | globenewswire.com

SLNO Shareholder Alert: Soleno Therapeutics, Inc. Securities Class Action Lawsuit - Investors With Losses May Contact The Gross Law Firm

May 5, 2026 | prnewswire.com

Portnoy Law Firm Announces Class Action on Behalf of Soleno Therapeutics, Inc. Investors

May 5, 2026 | globenewswire.com

SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, NATIONAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - SLNO

May 4, 2026 | newsfilecorp.comN

SOLENO THERAPEUTICS CLASS ACTION DEADLINE TOMORROW: Bragar Eagel & Squire, P.C. Urges Soleno Therapeutics, Inc. Investors with Significant Losses to Contact the Firm Before May 5th Lead Plaintiff Deadline

May 4, 2026 | globenewswire.com

Deadline Soon: Soleno Therapeutics, Inc. (SLNO) Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz About Securities Fraud Lawsuit

May 4, 2026 | tmcnet.com

SOLENO THERAPEUTICS DEADLINE TOMORROW: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Soleno Therapeutics, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action – SLNO

May 4, 2026 | globenewswire.com

SLNO INVESTOR NOTICE: Faruqi & Faruqi, LLP Reminds Soleno Therapeutics (SLNO) Investors of Securities Class Action Deadline on May 5, 2026

May 4, 2026 | newsfilecorp.comN

Bronstein, Gewirtz & Grossman LLC Urges Soleno Therapeutics, Inc. Investors to Act: Class Action Filed Alleging Investor Harm

May 4, 2026 | globenewswire.com

SLNO Deadline: SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit

May 4, 2026 | prnewswire.com

SLNO SHAREHOLDER NOTICE: Hagens Berman Alerts Soleno (SLNO) Investors to Pending Securities Fraud Class Action and Upcoming May 5th Lead Plaintiff Deadline

May 4, 2026 | globenewswire.com

Soleno Therapeutics, Inc. Sued for Securities Law Violations - Contact the DJS Law Group to Discuss Your Rights - SLNO

May 4, 2026 | prnewswire.com

SLNO Investors Have Opportunity to Lead Soleno Therapeutics, Inc. Securities Fraud Lawsuit with the Schall Law Firm

May 4, 2026 | prnewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLNO, AXSM, RDY, and CRNX Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

$206.68 0.00 (0.00%)

Closing price 09/4/2026 04:00 PM Eastern

Extended Trading

$206.83 +0.15 (+0.07%)

As of 04:09 AM Eastern

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea. It is also developing AXS-05, which is in Phase III clinical trial to treat Alzheimer's disease agitation, as well as that has completed phase II clinical trial for the treatment of smoking cessation; AXS-07, an investigational medicine that has completed Phase III trials for the acute treatment of migraine; AXS-12, an investigational medicine, which is in Phase III trial to treat narcolepsy; AXS-14, a selective and potent norepinephrine reuptake inhibitor that has completed Phase III trial for the treatment of fibromyalgia and other conditions; and solriamfetol, a dual-acting dopamine and norepinephrine reuptake inhibitor, which has completed a Phase 2 trial for treating attention-deficit/hyperactivity disorder, and is in phase 2 major depressive, binge eating, and shift work disorder. Axsome Therapeutics, Inc. has a research collaboration agreement with Duke University for evaluating AXS-05 in smoking cessation. The company was incorporated in 2012 and is based in New York, New York.

Crinetics Pharmaceuticals NASDAQ:CRNX

$84.95 0.00 (0.00%)

As of 09/1/2026

Crinetics Pharmaceuticals, Inc., a clinical-stage pharmaceutical company, focuses on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors. The company's lead product candidate is paltusotine, an oral selective nonpeptide somatostatin receptor type 2 agonist, which is in Phase 3 trial for the treatment of acromegaly; and Phase 2 trial for treating carcinoid syndrome associated with neuroendocrine tumors. It is also developing CRN04894, an investigational oral nonpeptide product candidate to antagonize the adrenocorticotrophic hormone (ACTH) receptor that has completed a Phase 1 study for the treatment of diseases caused by excess ACTH, including congenital adrenal hyperplasia and Cushing's disease. In addition, the company is developing antagonists of the parathyroid hormone (PTH) receptor for the treatment of primary hyperparathyroidism and humoral hypercalcemia of malignancy, and other diseases of excess PTH; identified investigational orally available somatostatin receptor type 3 targeted nonpeptide agonists for the treatment of autosomal dominant polycystic kidney disease; and developing thyroid-stimulating hormone receptor antagonists for the treatment of graves' disease and thyroid eye disease, as well as Oral GLP-1 and GIP nonpeptides for the treatment of diabetes and obesity. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Dr. Reddy's Laboratories NYSE:RDY

$11.97 0.00 (0.00%)

As of 09/4/2026 03:58 PM Eastern

Dr. Reddy's Laboratories Limited, together with its subsidiaries, operates as an integrated pharmaceutical company worldwide. It operates through Global Generics, Pharmaceutical Services and Active Ingredients (PSAI), and Others segments. The company's Global Generics segment manufactures and markets prescription and over-the-counter finished pharmaceutical products that are marketed under a brand name or as a generic finished dosages with therapeutic equivalence to branded formulations, as well as engages in the biologics business. The PSAI segment manufactures and markets active pharmaceutical ingredients and intermediates, which are principal ingredients for finished pharmaceutical products. This segment also provides contract research services; and manufactures and sells active pharmaceutical ingredients and steroids in accordance with the specific customer requirements. The Others segment engages in developing therapies in the fields of oncology and inflammation; research and development of differentiated formulations; and provides digital healthcare and information technology enabled business support services. The company offers its products for various therapeutic categories primarily include gastro-intestinal, cardiovascular, anti-diabetic, dermatology, oncology, respiratory, stomatology, urology, and nephrology. Dr. Reddy's Laboratories Limited was incorporated in 1984 and is headquartered in Hyderabad, India.

Soleno Therapeutics NASDAQ:SLNO

Soleno Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutics for the treatment of rare diseases. Its lead candidate is Diazoxide Choline Extended-Release tablets, a once-daily oral tablet, which is in Phase III clinical trials for the treatment of Prader-Willi Syndrome. The company was formerly known as Capnia, Inc. and changed its name to Soleno Therapeutics, Inc. in May 2017. Soleno Therapeutics, Inc. was incorporated in 1999 and is based in Redwood City, California.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLNO, AXSM, RDY, and CRNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLNO, AXSM, RDY, and CRNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLNO, AXSM, RDY, and CRNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLNO, AXSM, RDY, and CRNX Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Crinetics Pharmaceuticals NASDAQ:CRNX

Dr. Reddy's Laboratories NYSE:RDY

Soleno Therapeutics NASDAQ:SLNO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest SLNO, AXSM, RDY, and CRNX Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest SLNO, AXSM, RDY, and CRNX Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

SLNO, AXSM, RDY, and CRNX Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

SLNO, AXSM, RDY, and CRNX Company Descriptions

Axsome Therapeutics NASDAQ:AXSM

Crinetics Pharmaceuticals NASDAQ:CRNX

Dr. Reddy's Laboratories NYSE:RDY

Soleno Therapeutics NASDAQ:SLNO

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools